SCHEMBL23558978

SCHEMBL23558978

Cc1ccc(Cn2nc(-c3cnc(OCC(F)(F)F)nc3)ccc2=O)cn1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ MAPT P10636 2/20 0.41
▸ TP53 P04637 1/20 0.41
▸ MET P08581 8/20 0.41
▸ GRIN1 Q05586 2/20 0.40
▸ GRIN2B Q13224 2/20 0.40
▸ POLB P06746 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ PDE4A P27815 1/20 0.38
▸ PDE4B Q07343 1/20 0.38
▸ PDE4C Q08493 1/20 0.38
▸ PDE4D Q08499 1/20 0.38
▸ CHEK1 O14757 1/20 0.38
▸ NEK2 P51955 1/20 0.38
▸ LIMK1 P53667 1/20 0.38
▸ TYRO3 Q06418 1/20 0.38
▸ CLK4 Q9HAZ1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29569742 1.00 MEN1 (0.41) MEN1KMT2AMAPTTP53MET
SCHEMBL26529105 0.93 MET (0.40) MEN1KMT2AMAPTTP53MET
SCHEMBL23528790 0.88 MAPT (0.39) MEN1KMT2AMAPTTP53MET
SCHEMBL23528550 0.88 CYP11B1 (0.43) MEN1KMT2AMAPTTP53MET
SCHEMBL29569470 0.88 CYP11B1 (0.43) MEN1KMT2AMAPTTP53MET
SCHEMBL26999000 0.88 MAPT (0.39) MEN1KMT2AMAPTTP53MET
SCHEMBL23559024 0.87 POLB (0.40) MEN1KMT2AMAPTTP53MET
SCHEMBL29569959 0.87 POLB (0.40) MEN1KMT2AMAPTTP53MET
SCHEMBL23559419 0.87 MEN1 (0.40) MEN1KMT2AMAPTTP53MET
SCHEMBL23297268 0.86 TP53 (0.45) MEN1KMT2AMAPTTP53MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12012395-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2024-06-18 — — US disclosed
US-20240025879-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2024-01-25 — — US disclosed
US-20240025879-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2024-01-25 — — US disclosed
US-11873290-B2 — — 2024-01-16 — — US disclosed
US-11873290-B2 — — 2024-01-16 — — US disclosed
US-11873290-B2 — — 2024-01-16 — — US disclosed
US-20230321091-A1 SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. 2023-10-12 — — US disclosed
US-20230321091-A1 SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. 2023-10-12 — — US disclosed
EP-4248973-A2 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2023-09-27 — — EP disclosed
EP-3877376-B1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2023-08-23 — — EP disclosed
EP-3877376-B1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2023-08-23 — — EP disclosed
WO-2021231615-A1 SUBSTITUTED PYRIDAZINONE FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. (US) 2021-11-18 — — WO disclosed
US-11091464-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2021-08-17 — — US disclosed
US-11091464-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2021-08-17 — — US disclosed
US-20210188814-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2021-06-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188814-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF IL6, IL1B, IL1A MEN1 4368/4885KMT2A 4169/4885MAPT 1810/4885
US-20230321091-A1 SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES IL6, MUSK, SMN1; SMN2 MEN1 4467/4885KMT2A 3767/4885MAPT 1863/4885
US-12012395-B2 Pyridazinone compounds and uses thereof IL6, IL1B, IL1A MEN1 4368/4885KMT2A 4169/4885MAPT 1810/4885
US-11873290-B2 — IL6, MUSK, IL6ST MEN1 4771/4885KMT2A 4022/4885MAPT 2128/4885
US-11091464-B2 Pyridazinone compounds and uses thereof IL6, IL1B, IL1A MEN1 4368/4885KMT2A 4169/4885MAPT 1810/4885
US-20240025879-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF IL6, IL1B, IL1A MEN1 4368/4885KMT2A 4169/4885MAPT 1810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback